PRESS-RELEASE ·Filed Oct 21, 2026
Press release · Earnings
Latest settled — T+1d
NUVB ▼ -2.77% at T+1d
NEUTRAL call -2.77% · α vs SPY -2.24% · entry $4.70 → $4.57
T+1d
-2.77%
call -2.77% · α -2.24%
$4.57
settled 4d ago
T+5d
Pending
tomorrow
T+20d
Pending
in 23d
T+60d
Pending
in 3mo
Price Chart
Loading chart...
Executive Summary
Nuvation Bio, Inc. announced it will report its Q3 2026 results on November 4, 2026.
Key Facts
- Nuvation Bio, Inc. announced it will report its Q3 2026 results on November 4, 2026.
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302915774 |
8 reports for NUVB
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | Press Release | $4.70 | awaiting T+60 | — | $4.57 (−2.87%) |
Aug 6, 2026 11w ago | 8-K | $6.11 | awaiting T+60 | — | $4.57 (−25.29%) |
Jun 26, 2026 17w ago | 424B5 | $5.61 $6.10 | ▼ −8.73% | ▼ −4.35% | $4.57 (+18.63%) |
Jun 23, 2026 17w ago | 144 | $6.46 $6.07 | ▲ +6.04% | ▲ +8.88% | $4.57 (+29.33%) |
Jun 23, 2026 17w ago | 144 | $6.46 $6.07 | ▼ −6.04% | ▼ −8.88% | $4.57 (−29.33%) |
May 4, 2026 24w ago | 8-K | $4.83 $6.70 | ▲ +38.72% | ▲ +35.98% | $4.57 (−5.49%) |
Apr 21, 2026 26w ago | DEFA14A | $5.11 $5.64 | ▲ +10.37% | ▲ +3.47% | $4.57 (−10.67%) |
Apr 17, 2026 27w ago | 144 | $5.12 $5.90 | ▲ +15.23% | ▲ +8.46% | $4.57 (−10.84%) |
Showing 8 of 8
US Market Status
Market Open — Closes in 5h 16m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers